Ajanta Pharma Limited
Nippon India Mutual Fund marginally increased its stake in Ajanta Pharma from 2.78% to 2.79%, purchasing 14,544 shares.
A manufacturer of specialty pharmaceutical finished dosages, this company develops and markets formulations across therapeutic categories including ophthalmology, gastroenterology, and dermatology for domestic and international markets. With vertically integrated operations spanning development, manufacturing, and marketing, the company has established a significant presence in India's pharmaceutical sector through its robust distribution network and focus on quality production.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.